Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Epithelial Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Epithelial Neoplasm

Cancer Family

Epithelial Neoplasm

CI-CAN-00000016Explore in graph →

Non-malignant7,531 active trials118 approved drugs1,152 evidence items

NCIt: C3709

Overview
Statistics
Survival
Genomics314
Variants & evidence1152
Drugs206
Trials26887
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (916)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 151–175 of 916 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

A common variant in MTHFR influences response to chemoradiotherapy and recurrence of rectal cancer.
· Am J Cancer Res · 2015 · PMID 26693073 · validated civic_curation pubmed
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
· J Clin Oncol · 2011 · PMID 21172893 · validated civic_curation pubmed
Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.
· Hepatology · 2014 · PMID 24122810 · validated civic_curation pubmed
Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors.
· Lung Cancer · 2013 · PMID 24035188 · validated civic_curation pubmed
The T393C polymorphism in the gene GNAS1 of G protein is associated with survival of patients with invasive breast carcinoma.
· Breast Cancer Res Treat · 2007 · PMID 17186357 · validated civic_curation pubmed
Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
· J Thorac Oncol · 2011 · PMID 21258250 · validated civic_curation pubmed
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.

Showing 151–175 of 916 publications

← Previous
1
…
6
7
8
…
37
Next →

· J Clin Endocrinol Metab · 2008 · PMID 18682506 · validated civic_curation pubmed

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

· Lancet Oncol · 2012 · PMID 22452896 · validated civic_curation pubmed

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.

· J Clin Oncol · 2010 · PMID 20038723 · validated civic_curation pubmed

Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer.

· Mol Pathol · 2003 · PMID 14514923 · validated civic_curation pubmed

The T393C polymorphism of the G alpha s gene (GNAS1) is a novel prognostic marker in bladder cancer.

· Cancer Epidemiol Biomarkers Prev · 2005 · PMID 15824158 · validated civic_curation pubmed

The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma.

· Clin Cancer Res · 2006 · PMID 16467086 · validated civic_curation pubmed

The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer.

· Cancer Biomark · 2013 · PMID 24595080 · validated civic_curation pubmed

When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation?

· Ann Surg Oncol · 2009 · PMID 19472011 · validated civic_curation pubmed

Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.

· Clin Cancer Res · 2017 · PMID 28476872 · validated civic_curation pubmed

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

· Lancet Oncol · 2012 · PMID 22285168 · validated civic_curation pubmed

Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.

· Clin Cancer Res · 2011 · PMID 21531810 · validated civic_curation pubmed

Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review.

· Oncotarget · 2017 · PMID 28103578 · validated civic_curation pubmed

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.

· J Clin Oncol · 2017 · PMID 28475456 · validated civic_curation pubmed

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.

· Lancet Oncol · 2017 · PMID 28526536 · validated civic_curation pubmed

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.

· Ann Oncol · 2015 · PMID 25722381 · validated civic_curation pubmed

Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.

· Ann Oncol · 2016 · PMID 26802155 · validated civic_curation pubmed

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

· N Engl J Med · 2004 · PMID 15118073 · validated civic_curation pubmed

Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.

· Ann Oncol · 2015 · PMID 26209642 · validated civic_curation pubmed

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.

· J Clin Oncol · 2016 · PMID 26951309 · validated civic_curation pubmed